Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.Hematol Oncol Clin North Am. 2007; 21 (v): 609-632
- How I treat patients with thrombotic thrombocytopenic purpura: 2010.Blood. 2010; 116: 4060-4069
- Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management.Semin Thromb Hemost. 2012; 38: 469-482
- Complement activation in thrombotic thrombocytopenic purpura.J Thromb Haemost. 2012; 10: 791-798
- von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women.Thromb Haemost. 2004; 92: 1320-1326
- Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells.J Thromb Haemost. 2008; 6: 1233-1235
- Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice.J Clin Invest. 2005; 115: 2752-2761
- Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura.Blood. 2006; 107: 3161-3166
- A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13.Blood. 2012; 119: 6128-6135
- Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus).Blood. 2010; 116: 2005-2010
- Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS.Mol Immunol. 2012; 49: 640-648
- Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk.Proc Natl Acad Sci U S A. 2011; 108: 8761-8766
- Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome.J Am Soc Nephrol. 2010; 21: 2180-2187
- Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.Clin J Am Soc Nephrol. 2010; 5: 1844-1859
- Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.J Am Soc Nephrol. 2010; 21: 859-867
- Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.Ann Intern Med. 2000; 132: 794-799
- Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease.Rheumatology (Oxford). 2006; 45: 1046-1047
- Thrombotic thrombocytopenic purpura associated with anti-glomerular basement membrane disease.Nephrol Dial Transplant. 2010; 25: 3446-3449
- Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort.PLoS Med. 2011; 8: e1001013
- Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.Kidney Int Suppl. 2009; : S11-S14
- Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura.Br J Haematol. 2007; 138: 651-662
- Rituximab therapy for refractory thrombotic thrombocytopenic purpura.Blood Cells Mol Dis. 2002; 28: 385-391
- Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.Eur J Haematol. 2009; 83: 365-372
- A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.Blood. 2011; 118: 1746-1753
- Human immunodeficiency virus associated thrombotic thrombocytopenic purpura–favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.Br J Haematol. 2011; 153: 515-519
- Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.Am J Hematol. 2008; 83: 911-915
- Eculizumab efficacy and safety inpatients with atypical hemolyticuremic syndrome (aHUS) resistanttoplasmaexchange/infusion.Haematologica. 2011; 96: S2-S979
- A phase II study of eculizumab in patients with atypical hemolyticuremic syndrome receiving chronic plasma exchange/infusion.Haematologica. 2011; 96: S2-S980
- Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.Blood. 2011; 117: 6786-6792
- Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.J Am Soc Nephrol. 2009; 20: 940-949
- Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.Pediatr Nephrol. 2011; 26: 1325-1329
- Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome.Clin J Am Soc Nephrol. 2011; 6: 1488-1494
Article info
Identification
Copyright
© 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
